Labiotech.eu

Sickle cell disease after Casgevy: seven companies to watch in 2026

Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at its genetic root, ...
MedPage Today on MSN

First-in-Class Vepdegestrant Approved in Advanced Breast Cancer

Oral agent in second-line more than doubled median PFS in patients with ESR1 muta ...
Le Lézard

Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner's National Priority ...

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...
Le Lézard

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT ...

Immunocore Holdings plc: Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK- (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: ...